NYSE:BMY - Bristol-Myers Squibb Stock Price, Forecast & News

Bristol-Myers Squibb's stock was trading at $56.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BMY stock has decreased by 3.8% and is now trading at $54.39. View which stocks have been mosted impacted by Coronavirus.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bristol-Myers Squibb.

Bristol-Myers Squibb is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Bristol-Myers Squibb.

Bristol-Myers Squibb will be holding an earnings conference call on Thursday, May 7th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Bristol-Myers Squibb Co (NYSE:BMY) announced its quarterly earnings data on Thursday, February, 6th. The biopharmaceutical company reported $1.22 EPS for the quarter, topping the consensus estimate of $0.88 by $0.34. The biopharmaceutical company earned $7.95 billion during the quarter, compared to analysts' expectations of $6.20 billion. Bristol-Myers Squibb had a return on equity of 31.85% and a net margin of 13.15%. The company's quarterly revenue was up 33.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.94 earnings per share. View Bristol-Myers Squibb's earnings history.

Bristol-Myers Squibb announced a quarterly dividend on Monday, March 2nd. Investors of record on Friday, April 3rd will be paid a dividend of $0.45 per share on Friday, May 1st. This represents a $1.80 annualized dividend and a dividend yield of 3.31%. The ex-dividend date of this dividend is Thursday, April 2nd. View Bristol-Myers Squibb's dividend history.

Bristol-Myers Squibb updated its FY20 earnings guidance on Thursday, February, 6th. The company provided EPS guidance of $6.00-$6.20 for the period, compared to the Thomson Reuters consensus estimate of $6.20. The company issued revenue guidance of $40.5-$42.50 billion, compared to the consensus revenue estimate of $42.21 billion.

15 equities research analysts have issued twelve-month price objectives for Bristol-Myers Squibb's stock. Their forecasts range from $50.00 to $80.00. On average, they anticipate Bristol-Myers Squibb's share price to reach $62.75 in the next twelve months. This suggests a possible upside of 15.4% from the stock's current price. View analysts' price targets for Bristol-Myers Squibb.

Media headlines about BMY stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Bristol-Myers Squibb earned a daily sentiment score of -2.8 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutBristol-Myers Squibb.

Some companies that are related to Bristol-Myers Squibb include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Perrigo (PRGO), Horizon Therapeutics (HZNP), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Pfizer (PFE), Chicago Bridge & Iron (CBI), Bank of America (BAC), Verizon Communications (VZ), CVS Health (CVS), Walt Disney (DIS), NVIDIA (NVDA) and Cisco Systems (CSCO).

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

Bristol-Myers Squibb's stock is owned by many different institutional and retail investors. Top institutional investors include Wealth Quarterback LLC (6.76%), Charles Schwab Investment Management Inc. (1.21%), Loomis Sayles & Co. L P (0.84%), Capital World Investors (0.78%), Sumitomo Mitsui Trust Holdings Inc. (0.65%) and Franklin Resources Inc. (0.61%). Company insiders that own Bristol-Myers Squibb stock include Dinesh C Paliwal, John E Elicker, Karen Murphy Santiago, Louis S Schmukler, Robert J Bertolini and Theodore R Samuels II. View institutional ownership trends for Bristol-Myers Squibb.

BMY stock was sold by a variety of institutional investors in the last quarter, including Baupost Group LLC MA, Franklin Resources Inc., MUFG Securities EMEA plc, Jacobs Levy Equity Management Inc., Barrow Hanley Mewhinney & Strauss LLC, Loomis Sayles & Co. L P, PGGM Investments, and Alberta Investment Management Corp. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include John E Elicker, Karen Murphy Santiago, and Louis S Schmukler. View insider buying and selling activity for Bristol-Myers Squibb.

BMY stock was acquired by a variety of institutional investors in the last quarter, including Wealth Quarterback LLC, TIG Advisors LLC, Charles Schwab Investment Management Inc., Prudential Financial Inc., Sumitomo Mitsui Trust Holdings Inc., Senator Investment Group LP, Swiss National Bank, and California Public Employees Retirement System. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal, Robert J Bertolini, and Theodore R Samuels II. View insider buying and selling activity for Bristol-Myers Squibb.

Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BMY stock can currently be purchased for approximately $54.39.

Bristol-Myers Squibb has a market capitalization of $122.79 billion and generates $26.15 billion in revenue each year. The biopharmaceutical company earns $3.44 billion in net income (profit) each year or $4.69 on an earnings per share basis. Bristol-Myers Squibb employs 30,000 workers across the globe. View additional information about Bristol-Myers Squibb.

The official website for Bristol-Myers Squibb is http://www.bms.com/.

Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]